Brenzys a-flag controversy grows

Posted 22 August 2016

The PBAC's decision to recommend MSD's Brenzys with an a-flag has met with strong criticism but also some support.

The biosimilar competitor to Pfizer's Enbrel (etanercept) made the positive recommendations list released on Friday accompanied by a number of specific reasons for the a-flagging decision.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here